Literature DB >> 24900514

Lipophilic Isosteres of a π-π Stacking Interaction: New Inhibitors of the Bcl-2-Bak Protein-Protein Interaction.

Naeem Yusuff1, Michaël Doré1, Carol Joud1, Michael Visser1, Clayton Springer1, Xiaoling Xie1, Kara Herlihy1, Dale Porter1, B Barry Touré1.   

Abstract

The discovery of new Bcl-2 protein-protein interaction antagonists is described. We replaced the northern fragment of ABT737 (π-π stacking interactions) with structurally simplified hydrophobic cage structures with much reduced conformational flexibility and rotational freedom. The binding mode of the compounds was elucidated by X-ray crystallography, and the compounds showed excellent oral bioavailability and clearance in rat PK studies.

Entities:  

Keywords:  Bcl-2 inhibitors; bioisoteres; cancer therapeutics; protein−protein interaction; π−π stacking interactions; π−π stacking isosteres

Year:  2012        PMID： 24900514      PMCID： PMC4025652          DOI： 10.1021/ml300095a

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


  20 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

Review 2.  Cell death: critical control points.

Authors:  Nika N Danial; Stanley J Korsmeyer
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

Review 3.  Principles of protein-protein interactions: what are the preferred ways for proteins to interact?

Authors:  Ozlem Keskin; Attila Gursoy; Buyong Ma; Ruth Nussinov
Journal:  Chem Rev       Date:  2008-03-21       Impact factor: 60.622

4.  ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

Authors:  Christin Tse; Alexander R Shoemaker; Jessica Adickes; Mark G Anderson; Jun Chen; Sha Jin; Eric F Johnson; Kennan C Marsh; Michael J Mitten; Paul Nimmer; Lisa Roberts; Stephen K Tahir; Yu Xiao; Xiufen Yang; Haichao Zhang; Stephen Fesik; Saul H Rosenberg; Steven W Elmore
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

5.  Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein-protein interaction.

Authors:  Michael D Wendt
Journal:  Expert Opin Drug Discov       Date:  2008-09       Impact factor: 6.098

Review 6.  Bcl-2 and drugs used in the treatment of cancer: new strategies of biotherapy which should not be underestimated.

Authors:  A M Berghella; P Pellegrini; I Contasta; T Del Beato; D Adorno
Journal:  Cancer Biother Radiopharm       Date:  1998-08       Impact factor: 3.099

7.  Design, synthesis, and computational studies of inhibitors of Bcl-XL.

Authors:  Cheol-Min Park; Tetsuro Oie; Andrew M Petros; Haichao Zhang; Paul M Nimmer; Rodger F Henry; Steven W Elmore
Journal:  J Am Chem Soc       Date:  2006-12-20       Impact factor: 15.419

Review 8.  Bcl-2 family proteins and leukemia. Minireview.

Authors:  J Kusenda
Journal:  Neoplasma       Date:  1998       Impact factor: 2.575

9.  Rigid molecular tripod with an adamantane framework and thiol legs. Synthesis and observation of an ordered monolayer on Au111.

Authors:  Toshikazu Kitagawa; Yuichi Idomoto; Hiroaki Matsubara; Daisuke Hobara; Takashi Kakiuchi; Takao Okazaki; Koichi Komatsu
Journal:  J Org Chem       Date:  2006-02-17       Impact factor: 4.354

Review 10.  Mechanisms of apoptosis avoidance in cancer.

Authors:  J C Reed
Journal:  Curr Opin Oncol       Date:  1999-01       Impact factor: 3.645
View more
  2 in total

1.  The role of the acidity of N-heteroaryl sulfonamides as inhibitors of bcl-2 family protein-protein interactions.

Authors:  B Barry Touré; Karen Miller-Moslin; Naeem Yusuff; Lawrence Perez; Michael Doré; Carol Joud; Walter Michael; Lucian DiPietro; Simon van der Plas; Michael McEwan; Francois Lenoir; Madelene Hoe; Rajesh Karki; Clayton Springer; John Sullivan; Kymberly Levine; Catherine Fiorilla; Xiaoling Xie; Raviraj Kulathila; Kara Herlihy; Dale Porter; Michael Visser
Journal:  ACS Med Chem Lett       Date:  2013-01-04       Impact factor: 4.345

2.  Synthesis/biological evaluation of hydroxamic acids and their prodrugs as inhibitors for Botulinum neurotoxin A light chain.

Authors:  Hajime Seki; Sabine Pellett; Peter Silhár; G Neil Stowe; Beatriz Blanco; Matthew A Lardy; Eric A Johnson; Kim D Janda
Journal:  Bioorg Med Chem       Date:  2013-12-08       Impact factor: 3.641
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.